• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Demystifying Danaher: Insights From 5 Analyst Reviews

    7/24/24 11:00:30 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials
    Get the next $DHR alert in real time by email

    In the last three months, 5 analysts have published ratings on Danaher (NYSE:DHR), offering a diverse range of perspectives from bullish to bearish.

    The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 1 1 3 0 0
    Last 30D 1 0 3 0 0
    1M Ago 0 1 0 0 0
    2M Ago 0 0 0 0 0
    3M Ago 0 0 0 0 0

    Analysts have set 12-month price targets for Danaher, revealing an average target of $269.0, a high estimate of $310.00, and a low estimate of $250.00. This current average reflects an increase of 4.59% from the previous average price target of $257.20.

    price target chart

    Breaking Down Analyst Ratings: A Detailed Examination

    A comprehensive examination of how financial experts perceive Danaher is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

    Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
    Daniel Arias Stifel Raises Hold $250.00 $235.00
    Matthew Sykes Goldman Sachs Raises Neutral $250.00 $225.00
    Dan Brennan TD Cowen Raises Buy $310.00 $290.00
    Derik De Bruin B of A Securities Raises Neutral $275.00 $270.00
    Vijay Kumar Evercore ISI Group Lowers Outperform $260.00 $266.00

    Key Insights:

    • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Danaher. This information offers a snapshot of how analysts perceive the current state of the company.
    • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Danaher compared to the broader market.
    • Price Targets: Gaining insights, analysts provide estimates for the future value of Danaher's stock. This comparison reveals trends in analysts' expectations over time.

    Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Danaher's market position. Stay informed and make well-informed decisions with our Ratings Table.

    Stay up to date on Danaher analyst ratings.

    All You Need to Know About Danaher

    In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.

    Financial Milestones: Danaher's Journey

    Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

    Decline in Revenue: Over the 3 months period, Danaher faced challenges, resulting in a decline of approximately -2.57% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

    Net Margin: Danaher's net margin excels beyond industry benchmarks, reaching 18.77%. This signifies efficient cost management and strong financial health.

    Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.04%, the company showcases effective utilization of equity capital.

    Return on Assets (ROA): Danaher's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.3%, the company showcases efficient use of assets and strong financial health.

    Debt Management: Danaher's debt-to-equity ratio is below the industry average at 0.34, reflecting a lower dependency on debt financing and a more conservative financial approach.

    Understanding the Relevance of Analyst Ratings

    Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

    Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

    If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $DHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DHR

    DatePrice TargetRatingAnalyst
    12/9/2025$265.00Buy
    Goldman
    12/2/2025$270.00Overweight
    Morgan Stanley
    10/8/2025$220.00Buy → Neutral
    Rothschild & Co Redburn
    7/11/2025$275.00Sector Perform → Sector Outperform
    Scotiabank
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    3/21/2025$260.00Neutral → Buy
    Goldman
    3/14/2025$260.00Hold → Buy
    Stifel
    2/3/2025Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Riley Christopher Paul was granted 1,046 shares, increasing direct ownership by 7% to 15,585 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    2/6/26 5:01:33 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SVP, Chief Science Officer Gutierrez-Ramos Jose-Carlos was granted 1,695 shares, increasing direct ownership by 15% to 12,999 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    2/6/26 5:01:17 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Senior Vice President Ellis Brian W was granted 1,695 shares, increasing direct ownership by 13% to 14,994 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    2/6/26 5:01:27 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Danaher with a new price target

    Goldman initiated coverage of Danaher with a rating of Buy and set a new price target of $265.00

    12/9/25 8:43:56 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Morgan Stanley initiated coverage on Danaher with a new price target

    Morgan Stanley initiated coverage of Danaher with a rating of Overweight and set a new price target of $270.00

    12/2/25 8:25:25 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Danaher from Buy to Neutral and set a new price target of $220.00

    10/8/25 8:23:31 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    SEC Filings

    View All

    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Danaher Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    2/10/26 4:22:59 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Danaher Corporation

    SCHEDULE 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    1/30/26 1:28:57 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    1/12/26 9:07:26 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Reports Fourth Quarter and Full Year 2025 Results

    WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Fourth Quarter 2025 Results Net earnings were $1.2 billion, or $1.66 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 4.0% to $2.23.Revenues increased 4.5% year-over-year to $6.8 billion and non-GAAP core revenue increased 2.5% year-over-year.Operating cash flow was $2.1 billion and non-GAAP free cash flow was $1.8 billion.Key Full Year 2025 Results Net earni

    1/28/26 6:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher CEO to Comment on Financial Performance

    WASHINGTON, Jan. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2025 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT. For the fourth quarter 2025, estimated revenues are anticipated to increase in the mid-single digit percent range year-over-year.Estimated non-GAAP core revenue growth for the fourth quarter of 2025 is expected to be toward the high-end of our previously announced low-single digit percentage guidance.For the full year 2025, anticipated non-GAAP adjusted diluted net earnings per common

    1/12/26 9:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher to Present at J.P. Morgan Healthcare Conference

    WASHINGTON, Jan. 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 13, 2026 at 11:15 a.m. PT. The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most i

    1/5/26 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Leadership Updates

    Live Leadership Updates

    View All

    AstroNova Appoints Jorik E. Ittmann as President and Chief Executive Officer

    Leverages Mr. Ittmann's extensive print industry and international business experience Padraig Finn, with over 16 years in the print industry, promoted to Senior Vice President, Product Identification Tom Carll, Senior Vice President, Aerospace, Thomas DeByle, CFO, and Michael Natalizia, Chief Technology Officer, round out the Executive Leadership Team Darius G. Nevin appointed Executive Chairman AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, today announced that the Board of Directors has promoted Jorik E. Ittmann to President and CEO and appointed him to the Board of Directors, both to be effective

    8/4/25 9:00:00 AM ET
    $ALOT
    $DHR
    $VLTO
    Computer peripheral equipment
    Technology
    Industrial Machinery/Components
    Industrials

    Danaher Appoints Jonathan Leiken as General Counsel

    WASHINGTON, July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. "Jon brings nearly three deca

    7/31/25 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

    WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

    6/27/25 7:35:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Financials

    Live finance-specific insights

    View All

    Danaher Reports Fourth Quarter and Full Year 2025 Results

    WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Fourth Quarter 2025 Results Net earnings were $1.2 billion, or $1.66 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 4.0% to $2.23.Revenues increased 4.5% year-over-year to $6.8 billion and non-GAAP core revenue increased 2.5% year-over-year.Operating cash flow was $2.1 billion and non-GAAP free cash flow was $1.8 billion.Key Full Year 2025 Results Net earni

    1/28/26 6:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher CEO to Comment on Financial Performance

    WASHINGTON, Jan. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2025 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT. For the fourth quarter 2025, estimated revenues are anticipated to increase in the mid-single digit percent range year-over-year.Estimated non-GAAP core revenue growth for the fourth quarter of 2025 is expected to be toward the high-end of our previously announced low-single digit percentage guidance.For the full year 2025, anticipated non-GAAP adjusted diluted net earnings per common

    1/12/26 9:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Schedules Fourth Quarter 2025 Earnings Conference Call

    WASHINGTON, Dec. 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2025 on Wednesday, January 28, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

    12/17/25 7:30:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/23 11:16:32 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/22 3:43:35 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

    SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)

    11/2/21 9:29:29 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials